Six months is the sweet spot for repeat FibroScan. At 3 months, changes in liver stiffness may not be reliably detectable above the test's measurement variability (~1.5 kPa). Doing it too early can create false reassurance or unnecessary alarm. As for tirzepatide vs. semaglutide for MASH: The honest answer is we don't have head-to-head biopsy data yet. What we know: Semaglutide: More published MASH-specific data. The Phase 2 trial showed ~59% MASH resolution at 0.4mg (higher than the 2.4mg standard dose). ESSENCE Phase 3 data is the most anticipated dataset. Tirzepatide: The SYNERGY-NASH Phase 2 showed MASH resolution rates of ~74% at the 15mg dose, with fibrosis improvement in ~47%. The GIP component may offer additional anti-inflammatory effects in the liver beyond what GLP-1 alone provides. Based on the Phase 2 data, tirzepatide appears to have a modest edge, but these are different trials with different populations, so direct comparison is unreliable. Bottom line: both are excellent choices. Your response at 3 months suggests tirzepatide is working well for you. Don't second-guess the choice — focus on adherence, lifestyle, and monitoring.